InvestorsHub Logo
Followers 14
Posts 2297
Boards Moderated 0
Alias Born 12/20/2012

Re: Here Today post# 278731

Thursday, 12/26/2019 9:07:55 AM

Thursday, December 26, 2019 9:07:55 AM

Post# of 402939
"Ehrlich continued: “Given the industry buzz around the recent IPOs of Galera Therapeutics and Monopar Therapeutics, each with late-stage drug candidates targeting Oral Mucositis, we feel confident about the competitive positioning and commercial prospects of oral rinse Brilacidin as a preventative OM drug candidate and the considerable value it can bring to our company. The investment community seems to be waking up to the large unmet need in this area. We anticipate an active partnering process, with meetings scheduled with pharmaceutical companies interested in Brilacidin-OM during the 2020 J.P. Morgan Healthcare conference this January in San Francisco. A licensing deal for the Brilacidin-OM asset would bring significant upside for our shareholders.”


We- Who is "we"? How many employees are left in that ~1/4 acre office building? Is Jane Harness with ipix? What is the company's chain of command?

the 2020 J.P. Morgan Healthcare conference - Sounds as though it's back to square one.







Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News